Dai ichi Life Insurance Company Ltd Sells 6,358 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Dai ichi Life Insurance Company Ltd lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,119 shares of the company’s stock after selling 6,358 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Neurocrine Biosciences were worth $4,853,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences in the 2nd quarter valued at approximately $28,000. Innealta Capital LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at $30,000. New Covenant Trust Company N.A. purchased a new position in shares of Neurocrine Biosciences during the 1st quarter valued at $32,000. EdgeRock Capital LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at $35,000. Finally, Plato Investment Management Ltd purchased a new position in shares of Neurocrine Biosciences during the 1st quarter valued at $41,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Up 0.6 %

Shares of NASDAQ:NBIX opened at $127.91 on Wednesday. The company has a market cap of $12.95 billion, a price-to-earnings ratio of 34.29 and a beta of 0.35. The company has a 50-day moving average price of $118.83 and a 200-day moving average price of $131.74. Neurocrine Biosciences, Inc. has a 12 month low of $110.52 and a 12 month high of $157.98.

Analysts Set New Price Targets

NBIX has been the subject of a number of recent analyst reports. Jefferies Financial Group boosted their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Citigroup boosted their price target on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Monday, September 16th. JPMorgan Chase & Co. upped their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada cut their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.